Whole-proteome analysis of mesonephric-derived cancers describes new potential biomarkers

被引:11
作者
Gibbard, Evan [1 ,2 ]
Cochrane, Dawn R. [2 ]
Pors, Jennifer [3 ]
Negri, Gian Luca [3 ,4 ]
Colborne, Shane [4 ]
Cheng, Angela S. [5 ]
Chow, Christine [5 ]
Farnell, David [3 ]
Tessier-Cloutier, Basile [3 ]
McAlpine, Jessica N. [6 ]
Morin, Gregg B. [1 ,4 ]
Schmidt, Dietmar [7 ]
Kommoss, Stefan [8 ]
Kommoss, Friedrich [9 ]
Keul, Jacqueline [10 ]
Gilks, Blake [3 ,5 ,11 ]
Huntsman, David G. [1 ,2 ,3 ,5 ]
Hoang, Lynn [3 ,5 ,11 ]
机构
[1] Univ British Columbia, Dept Med Genet, Vancouver, BC V6H 3N1, Canada
[2] BC Canc Agcy, Mol Oncol, Vancouver, BC V5Z 1L3, Canada
[3] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada
[4] BC Canc Agcy, Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 4S6, Canada
[5] Vancouver Gen Hosp, Genet Pathol Evaluat Ctr, Vancouver, BC V6H 3Z6, Canada
[6] Univ British Columbia, Dept Gynecol & Obstet, Div Gynecol Oncol, Vancouver, BC V6Z 2K8, Canada
[7] MVZ Histol Cytol & Mol Diagnost, D-54296 Trier, Germany
[8] Univ Tubingen, Dept Obstet & Gynecol, D-72076 Tubingen, Germany
[9] Med Campus Bodensee, Inst Pathol, D-88048 Friedrichshafen, Germany
[10] Tubingen Univ Hosp, Dept Womens Hlth, D-72076 Tubingen, Germany
[11] Vancouver Gen Hosp, Dept Anat Pathol, Vancouver, BC V5Z 1M9, Canada
关键词
Mesonephric carcinoma; Female adnexal tumors of probable Wolffian origin; Mesonephric ducts; Proteomics; Biomarkers; Diagnosis; PROBABLE WOLFFIAN ORIGIN; RECURRENT KRAS MUTATIONS; FEMALE ADNEXAL TUMORS; CASE SERIES; UTERINE; GATA3; ADENOCARCINOMAS; CARCINOMAS; MARKER; FATWO;
D O I
10.1016/j.humpath.2020.10.005
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Mesonephric carcinomas (MEs) and female adnexal tumors of probable Wolffian origin (FATWO) are derived from embryologic remnants of Wolffian/mesonephric ducts. Mesonephric-like carcinomas (MLCs) show identical morphology to ME of the cervix but occur in the uterus and ovary without convincing mesonephric remnants. ME, MLC, and FATWO are challenging to diagnose due to their morphologic similarities to Miillerian/paramesonephric tumors, contributing to a lack of evidence-based and tumor-specific treatments. We performed whole-proteomic analysis on 9 ME/MLC and 56 endometrial carcinomas (ECs) to identify potential diagnostic biomarkers. Although there were no convincing differences between ME and MLC, 543 proteins showed increased expression in ME/MLC relative to EC. From these proteins, euchromatic histone lysine methyltransferase 2 (EHMT2), glutathione S-transferase Mu 3 (GSTM3), eukaryotic translation elongation factor 1 alpha 2 (EEF1A2), and glycogen synthase kinase 3 beta were identified as putative biomarkers. Immunohistochemistry was performed on these candidates and GATA3 in 14 ME/MLC, 8 FATWO, 155 EC, and normal tissues. Of the candidates, only GATA3 and EHMT2 were highly expressed in mesonephric remnants and mesonephric-derived male tissues. GATA3 had the highest sensitivity and specificity for ME/MLC versus EC (93% and 99%) but was absent in FATWO. EHMT2 was 100% sensitive for ME/MLC & FATWO but was not specific (65%). Similarly, EEF1A2 was reasonably sensitive to ME/MLC (92%) and FATWO (88%) but was the least specific (38%). GSTM3 performed intermediately (sensitivity for ME/MLC and FATWO: 83% and 38%, respectively; specificity 67%). Although GATA3 remained the best diagnostic biomarker for ME/MLC, we have identified EHMT2, EEF1A2, and GSTM3 as proteins of interest in these cancers. FATWO's cell of origin is uncertain and remains an area for future research. Crown Copyright (C) 2020 Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 38 条
[1]   Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases [J].
Allocati, Nerino ;
Masulli, Michele ;
Di Ilio, Carmine ;
Federici, Luca .
ONCOGENESIS, 2018, 7
[2]   The role of GATA3 in breast carcinomas: a review [J].
Asch-Kendrick, Rebecca ;
Cimino-Mathews, Ashley .
HUMAN PATHOLOGY, 2016, 48 :37-47
[3]   Female adnexal tumors of probable Wolffian origin: morphological, immunohistochemical, and molecular analysis of 15 cases [J].
Bennett, Jennifer A. ;
Ritterhouse, Lauren L. ;
Furtado, Larissa V. ;
Lastra, Ricardo R. ;
Pesci, Anna ;
Newell, Jordan M. ;
Burandt, Eike ;
Kooreman, Loes ;
Van de Vijver, Koen ;
Krausz, Thomas ;
Felix, Ana ;
Zannoni, Gian Franco ;
Young, Robert H. ;
Oliva, Esther .
MODERN PATHOLOGY, 2020, 33 (04) :734-747
[4]   Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases [J].
Beurel, Eleonore ;
Grieco, Steven F. ;
Jope, Richard S. .
PHARMACOLOGY & THERAPEUTICS, 2015, 148 :114-131
[5]  
Blaustein A., 2011, Blaustein's pathology of the female genital tract
[6]   Nuclear GSK-3β inhibits the canonical Wnt signalling pathway in a β-catenin phosphorylation-independent manner [J].
Caspi, M. ;
Zilberberg, A. ;
Eldar-Finkelman, H. ;
Rosin-Arbesfeld, R. .
ONCOGENE, 2008, 27 (25) :3546-3555
[7]   Female Adnexal Tumors of Probable Wolffian Origin (FATWO): A Case Series With Next-Generation Sequencing Mutation Analysis [J].
Cossu, Antonio ;
Casula, Milena ;
Paliogiannis, Panagiotis ;
Tanda, Francesco ;
Palomba, Grazia ;
Sini, Maria C. ;
Pisano, Marina ;
Doneddu, Valentina ;
Palmieri, Giuseppe .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2017, 36 (06) :575-581
[8]   Wolffian adnexal tumor, so-called female adnexal tumor of probable wolffian origin (FATWO): Immunohistochemical evidence in support of a wolffian origin [J].
Devouassoux-Shisheboran, M ;
Silver, SA ;
Tavassoli, FA .
HUMAN PATHOLOGY, 1999, 30 (07) :856-863
[9]   Mesonephric-like Carcinoma of the Endometrium A Subset of Endometrial Carcinoma With an Aggressive Behavior [J].
Euscher, Elizabeth D. ;
Bassett, Roland ;
Duose, Dzifa Y. ;
Lan, Chieh ;
Wistuba, Ignacio ;
Ramondetta, Lois ;
Ramalingam, Preetha ;
Malpica, Anais .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2020, 44 (04) :429-443
[10]   The regulation of glycogen synthase kinase-3 nuclear export by Frat/GBP [J].
Franca-Koh, J ;
Yeo, M ;
Fraser, E ;
Young, N ;
Dale, TC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (46) :43844-43848